Filing Flows › Xenon Pharmaceuticals (XENE) › Stock forecast & fair value
Xenon Pharmaceuticals (XENE) stock forecast and fair value
Xenon Pharmaceuticals (XENE) trades at $36.44. 16 analysts' median price target is $72.00 (+98%), from $46.00 to $90.00. Across 7 valuation methods the middle fair value is $10.52 (-71%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Residual income | −$1.17 | −$1.17 | −$1.17 | -103% |
| Analysts' price targets | $46.00 | $71.75 | $90.00 | +97% |
| Tangible book (asset value) | $9.98 | $12.47 | $12.47 | -66% |
| Net cash (floor) | $8.41 | $9.34 | $9.34 | -74% |
| Stage-weighted value (pre-revenue) | $9.00 | $10.52 | $10.52 | -71% |
| Combined forecast (3 months) | $29.84 | $37.89 | $46.95 | +4% |
| Net current asset value (net-net) | $5.97 | $8.96 | $8.96 | -75% |
Xenon Pharmaceuticals' latest quarter
Xenon Pharmaceuticals, Q1 2025: revenue $7.5M, operating margin -969.8%, net loss $65.0M, operating cash flow −$61.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for XENE stock?
The median of 16 analysts' 12-month targets is $72.00, +98% from $36.44; the range is $46.00 to $90.00. The average rating is strong buy.
What is Xenon Pharmaceuticals' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$1.17 and $71.75, with a middle value of $10.52 against a price of $36.44. Each method's assumptions are on the page.
Does Xenon Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is XENE stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.